<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ectopic pregnancy: Methotrexate therapy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ectopic pregnancy: Methotrexate therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Ectopic pregnancy: Methotrexate therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Togas Tulandi, MD, MHCM, FRCSC, FACOG, FCAHS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Courtney A Schreiber, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>An ectopic pregnancy is a pregnancy outside of the uterine cavity. The majority of ectopic pregnancies occur in the fallopian tube, but other possible sites include interstitial (a pregnancy located in the proximal segment of the fallopian tube that is embedded within the muscular wall of the uterus), cervical, intramural, ovarian, or abdominal. Other abnormally implanted pregnancies, including hysterotomy (ie, cesarean, myomectomy) scar pregnancies can also occur. In rare cases, a multiple gestation may be heterotopic (includes both a uterine and extrauterine pregnancy).</p><p>Ectopic pregnancy is a potentially life-threatening condition. While surgical approaches are the gold-standard treatment, because of advances in early diagnosis, many patients are candidates for medical therapy with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX), and the overall success rate of medical treatment in properly selected patients is high.</p><p>Treatment of ectopic pregnancy with MTX will be reviewed here. Related topics regarding ectopic pregnancy are discussed in detail separately, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Epidemiology, risk factors, and pathology (see  <a class="medical medical_review" href="/z/d/html/5481.html" rel="external">"Ectopic pregnancy: Epidemiology, risk factors, and anatomic sites"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical manifestations and diagnosis (see  <a class="medical medical_review" href="/z/d/html/5487.html" rel="external">"Ectopic pregnancy: Clinical manifestations and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Choosing a treatment (see  <a class="medical medical_review" href="/z/d/html/112852.html" rel="external">"Ectopic pregnancy: Choosing a treatment"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical management (see  <a class="medical medical_review" href="/z/d/html/3306.html" rel="external">"Tubal ectopic pregnancy: Surgical treatment"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Expectant management (see  <a class="medical medical_review" href="/z/d/html/5455.html" rel="external">"Ectopic pregnancy: Expectant management of tubal pregnancy"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis and management of uncommon sites of ectopic and abnormally implanted intrauterine pregnancies (see  <a class="medical medical_review" href="/z/d/html/132045.html" rel="external">"Abdominal pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/5487.html" rel="external">"Ectopic pregnancy: Clinical manifestations and diagnosis", section on 'Heterotopic pregnancy'</a> and  <a class="medical medical_review" href="/z/d/html/112852.html" rel="external">"Ectopic pregnancy: Choosing a treatment", section on 'Heterotopic pregnancy'</a> and  <a class="medical medical_review" href="/z/d/html/131912.html" rel="external">"Cesarean scar pregnancy"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with pregnancy of unknown location (see  <a class="medical medical_review" href="/z/d/html/134770.html" rel="external">"Approach to the patient with pregnancy of unknown location"</a>)</p><p></p><p class="headingAnchor" id="H1314293147"><span class="h1">INDICATIONS AND ALTERNATIVES</span><span class="headingEndMark"> — </span>The indication for pharmacologic management of ectopic pregnancy is a clinical diagnosis of ectopic pregnancy in a patient who meets the selection criteria for MTX therapy and who is able and willing to comply with the close follow-up that is necessary after pharmacologic management  (<a class="graphic graphic_algorithm graphicRef114571" href="/z/d/graphic/114571.html" rel="external">algorithm 1</a>). </p><p>How to choose between MTX and surgery (or expectant management in a small proportion of patients) and contraindications to MTX (eg, hemodynamic instability, heterotopic pregnancy with a coexisting viable intrauterine pregnancy, breastfeeding, hypersensitivity to MTX) are also illustrated in the algorithm and are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/112852.html" rel="external">"Ectopic pregnancy: Choosing a treatment"</a> and  <a class="medical medical_review" href="/z/d/html/112852.html" rel="external">"Ectopic pregnancy: Choosing a treatment", section on 'Choosing between methotrexate and surgery'</a>.)</p><p class="headingAnchor" id="H1531385692"><span class="h1">CLINICAL PHARMACOLOGY</span></p><p class="headingAnchor" id="H3686157937"><span class="h2">Mechanism of action</span><span class="headingEndMark"> — </span>MTX is a <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> antagonist widely used for treatment of neoplasia, severe psoriasis, and rheumatoid arthritis. It inhibits deoxynucleic acid (DNA) synthesis and cell reproduction, primarily in actively proliferating cells such as malignant cells, trophoblasts, and fetal cells. MTX is rapidly cleared by the kidneys, with 90 percent of an intravenous dose excreted unchanged within 24 hours of administration [<a href="#rid1">1</a>].</p><p>In some protocols, reduced folates (<a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a>, also called folinic acid, N5-formyl-tetrahydrofolate, citrovorum factor) are given in combination with MTX to bypass the metabolic block induced by MTX and thus rescue normal cells from toxicity. (See  <a class="medical medical_review" href="/z/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate", section on 'Rationale for leucovorin rescue'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Dosing and administration</span><span class="headingEndMark"> — </span>Treatment of ectopic pregnancy uses an intermediate MTX dose (50 mg/m<sup>2</sup> body surface area [BSA] or 1 <strong>mg/kg</strong> body weight) with a maximum dose (based on the author's clinical experience) of 100 mg in patients with normal renal function. However, no studies have evaluated the maximum dose of MTX in patients with ectopic pregnancy. </p><p>By contrast, low doses (7.5 to 25 mg weekly) are typically used to treat rheumatologic disorders, and high-dose MTX (≥500 mg/m<sup>2</sup>) is used to treat some malignancies. (See  <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Dosing and administration'</a> and  <a class="medical medical_review" href="/z/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate", section on 'Definition of high-dose methotrexate'</a>.)</p><p>MTX can be given systemically (ie, intravenously, intramuscularly [IM], or orally) or by direct local injection into the ectopic pregnancy sac with either a transvaginal or transabdominal (eg, laparoscopic) approach. IM administration is the most common route for treatment of tubal pregnancy [<a href="#rid2">2</a>]. Local injection is not generally used for tubal pregnancy, as it has been found to be less effective than salpingostomy [<a href="#rid3">3</a>], requires administration by an experienced physician, and is highly operator dependent. In addition, patients bearing the risks of laparoscopic surgery should have definitive treatment (ie, removal of the ectopic gestation via salpingectomy or salpingostomy). Local injection is used in some cases of rare ectopic gestation locations (eg, cervical). (See  <a class="medical medical_review" href="/z/d/html/3283.html" rel="external">"Cervical pregnancy: Diagnosis and management", section on 'Treatment'</a>.)</p><p>When <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> is administered as part of the multiple-dose MTX protocol, it is typically administered by IM injection; it can also be given orally. Leucovorin calcium is the preparation used for this indication. (See <a class="local">'Patients with an interstitial pregnancy: Multiple-dose'</a> below.)</p><p class="headingAnchor" id="H1531386832"><span class="h2">Adverse reactions</span><span class="headingEndMark"> — </span>Adverse reactions to MTX are usually mild and self-limited. The most common are stomatitis and conjunctivitis. Rare side effects include gastritis, enteritis, dermatitis, pneumonitis, alopecia, elevated liver enzymes, and bone marrow suppression. Approximately 30 percent of patients in the single-dose protocol will have side effects; this rate is lower than with multiple-dose regimens (40 percent) [<a href="#rid4">4</a>]. (See <a class="local">'Preferred approach for most patients: Single-dose'</a> below and  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a>.)</p><p>Toxicities of high-dose MTX are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate", section on 'Overview of adverse effects'</a>.)</p><p class="headingAnchor" id="H3121398672"><span class="h2">Comparing single- versus multi-dose therapy</span><span class="headingEndMark"> — </span>For most patients, we prefer an initial approach with single-dose therapy rather two-dose or multiple-dose therapy for tubal ectopic pregnancy (see <a class="local">'Clinical protocol'</a> below). While the overall rate of resolution of ectopic pregnancy reported in the literature is approximately 90 percent for both single- and multi-dose protocols [<a href="#rid3">3-5</a>], multi-dose protocols appear to cause more adverse effects [<a href="#rid4">4</a>]. A single-dose approach is also less expensive, requires less intensive monitoring, and does not require <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> rescue. In clinical use, however, protocols may overlap. Fourteen percent of patients on single-dose regimens ultimately receive two or more doses, and 10 percent of patients on multi-dose regimens receive just a single dose [<a href="#rid4">4</a>].</p><p>Data from systematic reviews and a meta-analysis evaluating the various regimens show mixed results:</p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review of two randomized trials including 159 patients comparing single-dose with fixed multiple-dose regimens, treatment success was similar between groups (89 to 91 and 86 to 93 percent, respectively) [<a href="#rid3">3</a>]. There were no consistent findings regarding rates of complications between the two regimens.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, in another systematic review of 26 observational studies including 1300 patients with ectopic pregnancy, overall success rates were lower for single- compared with multi-dose regimens [<a href="#rid4">4</a>]. This difference was even larger after adjustment for factors such as human chorionic gonadotropin (hCG) level and presence of embryonic cardiac activity (odds ratio [OR] 4.7, 95% CI 1.8-12.6). However, fewer side effects were noted after single-dose compared with multi-dose treatment (31 versus 41 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis evaluating seven randomized trials that compared patients treated for ectopic pregnancy with a single-dose, two-dose, or multiple-dose MTX, the two-dose protocol was associated with higher treatment success compared with the single-dose protocol (OR 1.8, 95% CI 1.1-3) [<a href="#rid6">6</a>]. In addition, the two-dose protocol was more successful than single-dose protocol in patients with high hCG levels (defined as hCG levels &gt;3000 milli-international units/mL; OR 3.2, 95% CI 1.5-6.8), and in patients with a large adnexal mass (defined as &gt;2 cm; OR 2.9, 95% CI 1.2-6.9). Compared with the single-dose protocol, the multi-dose protocol was associated with a nonsignificant reduction in treatment failure (OR 0.6, 95% CI 0.3-1.1) and a higher chance of side effects (OR 2.1, 95% CI 1.2-3.5).</p><p></p><p>For patients with interstitial pregnancy, there are no high-quality data comparing single-dose versus multi-dose MTX therapy. In one prospective study including 17 patients with interstitial pregnancy treated with single-dose MTX, 16 patients (94 percent) experienced pregnancy resolution; a second dose was required in six patients [<a href="#rid7">7</a>]. One patient experienced rupture of the ectopic pregnancy following two doses of MTX and was managed surgically. </p><p class="headingAnchor" id="H683403528"><span class="h2">Role of combined drug therapy</span><span class="headingEndMark"> — </span>While combined use of MTX with other medications (eg, <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a>, <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a>) has been studied, we do <strong>not</strong> use combination therapy in our practice; combination therapy adds cost and potential complications to an already effective therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mifepristone</strong> – <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">Mifepristone</a> is a progesterone receptor antagonist used for the management of patients with pregnancy loss or undergoing pregnancy termination. In a meta-analysis of three randomized trials including 442 patients with tubal ectopic pregnancy, single-dose MTX alone or in combination with oral mifepristone (600 mg) had similar rates of success; side effects, need for a second injection of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, and operative rates were also similar between groups [<a href="#rid8">8</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gefitinib</strong> – <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">Gefitinib</a> is a selective inhibitor of epidermal growth factor receptor and is used in the treatment of non-small cell lung cancer and breast cancer [<a href="#rid9">9,10</a>]. As the placenta has the highest expression of epidermal growth factor of all nonmalignant tissues, its use (in combination with MTX) has been investigated for the treatment of patients with ectopic pregnancy. </p><p></p><p class="bulletIndent1">In a small case series including 12 patients with an ectopic pregnancy, combination therapy with MTX plus <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a> resulted in a faster decline of serum hCG than treatment of historical controls with MTX alone [<a href="#rid10">10</a>]. However, a subsequent randomized trial did not support these findings. In this trial including 325 patients with tubal ectopic pregnancy (median hCG level 1994 milli-international units/mL), those receiving MTX plus seven days of either gefitinib (250 mg daily) or placebo had similar rates of surgical intervention, time to resolution, and subsequent doses of MTX [<a href="#rid11">11</a>]. While serious complications occurred in 4 to 5 percent of patients and were similar between groups, more patients in the gefitinib group experienced diarrhea (47 versus 24 percent) and rash (61 versus 23 percent). </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">Gefitinib</a> may result in interstitial lung disease, particularly in patients of Japanese ancestry. </p><p></p><p class="headingAnchor" id="H2515625040"><span class="h1">PRETREATMENT EVALUATION</span><span class="headingEndMark"> — </span>Prior to treatment with MTX, the following evaluation is performed:</p><p class="bulletIndent1"><span class="glyph">●</span>Physical examination and patient history</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum beta-human chorionic gonadotropin (hCG)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transvaginal ultrasound</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood type and screen</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count and renal (creatinine) and liver (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) function tests</p><p></p><p>These are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5487.html" rel="external">"Ectopic pregnancy: Clinical manifestations and diagnosis", section on 'Diagnostic evaluation'</a>.)</p><p class="headingAnchor" id="H2913806119"><span class="h1">CLINICAL PROTOCOL</span><span class="headingEndMark"> — </span>The regimens below are named for the <strong>intended</strong> number of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> doses and not the actual number of doses needed.</p><p>Protocols may vary and the choice of protocol depends on provider and institutional preference.</p><p class="headingAnchor" id="H13"><span class="h2">Preferred approach for most patients: Single-dose</span><span class="headingEndMark"> — </span>For most patients with tubal pregnancy, we suggest a single intramuscular (IM) dose of MTX. Approximately 15 to 20 percent of such patients will require a second dose of MTX, and patients should be made aware of this before starting the protocol [<a href="#rid4">4,12</a>]. Less than 1 percent of patients need more than two doses [<a href="#rid4">4</a>].</p><p>In the single-dose protocol  (<a class="graphic graphic_table graphicRef56738" href="/z/d/graphic/56738.html" rel="external">table 1</a>), day 1 is the day that MTX is administered; a human chorionic gonadotropin (hCG) is also measured on day 1 [<a href="#rid2">2,13,14</a>]. The dose used is 50 mg/m<sup>2</sup> body surface area (BSA; maximum dose 100 mg in patients with normal renal function). BSA may be calculated based on height and weight on the day of treatment using a BSA calculator (<a class="calc calc_professional" href="/z/d/html/13406.html" rel="external">calculator 1</a>) or the following formula:</p><div class="formulaContainer"><div class="formula"><p>BSA = square root ([cm × kg]/3600)</p></div></div><p class="bulletIndent1"><span class="glyph">●</span>In a commonly used protocol, on days 4 and 7, a serum hCG concentration is drawn [<a href="#rid15">15-17</a>]. If the decrease in hCG between days 4 and 7 is &lt;15 percent, a <strong>second</strong> dose of MTX 50 mg/m<sup>2</sup> IM is administered. It is common to observe an increase in hCG levels from day 1 through day 4, and this should not cause concern [<a href="#rid18">18</a>]. This is due to continued hCG production by syncytiotrophoblast despite cessation of production by cytotrophoblast.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If an additional dose of MTX is indicated, we do <strong>not</strong> repeat pretreatment laboratory testing (complete blood count, renal and liver function tests (see <a class="local">'Pretreatment evaluation'</a> above); there are no data suggesting that one dose of MTX changes the results of these tests.</p><p></p><p>Follow-up includes:</p><p class="bulletIndent1"><span class="glyph">●</span>After day 7, hCG testing is repeated weekly. On day 14:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If there is a ≥15 percent hCG decline from days 7 to 14, check hCG weekly until the level is undetectable (this level varies by laboratory). The hCG concentration usually declines to &lt;15 milli-international units/mL by 35 days postinjection, but some patients have a slow clearance of serum hCG and it may take as long as 109 days to become undetectable [<a href="#rid12">12,19</a>]. The risk of gestational trophoblastic disease is low.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If hCG does not become undetectable, a new pregnancy should be excluded.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In our practice, if three weekly values are similar, we give an additional dose of MTX (50 mg/m<sup>2</sup>). This typically accelerates the decline of serum hCG.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If there is a &lt;15 percent hCG decline from days 7 to 14, an additional dose of MTX 50 mg/m<sup>2</sup> IM is given.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the hCG is rising, a transvaginal ultrasound should be performed.</p><p></p><p>We give a maximum of three doses of MTX. In rare cases in which the hCG falls &lt;15 percent between weekly measurements after a third dose, we perform a laparoscopic salpingostomy or salpingectomy. (See  <a class="medical medical_review" href="/z/d/html/3306.html" rel="external">"Tubal ectopic pregnancy: Surgical treatment"</a>.)</p><p><a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">Leucovorin</a> rescue is <strong>not</strong> required for patients treated with the single-dose protocol, even if multiple doses are ultimately given.</p><p>There appears to be no clinical benefit from routine serial ultrasound examinations [<a href="#rid20">20</a>]. After treatment, the ectopic pregnancy is often noted to increase in size and may persist for weeks on serial ultrasound examinations. This probably represents hematoma rather than persistent trophoblastic tissue and is not predictive of treatment failure. However, ultrasound evaluation for peritoneal fluid is indicated for patients with severe abdominal pain. (See <a class="local">'Posttreatment instructions and counseling'</a> below.)</p><p class="headingAnchor" id="H1069160457"><span class="h3">Role of two-dose protocol</span><span class="headingEndMark"> — </span>Administration of a two-dose protocol has been described for selected patients with tubal ectopic pregnancy in whom human chorionic hCG levels are high (&gt;3000 milli-international units/mL) or with an adnexal mass measuring &gt;2 cm  (<a class="graphic graphic_table graphicRef56738" href="/z/d/graphic/56738.html" rel="external">table 1</a>); however, we do <strong>not</strong> use the two-dose protocol in our practice. (See <a class="local">'Comparing single- versus multi-dose therapy'</a> above.)</p><p>In this protocol, MTX 50 mg/m<sup>2</sup> BSA (maximum dose 100 mg in patients with normal renal function) is administered on day 1 and a <strong>second</strong> dose of MTX 50 mg/m<sup>2</sup> on day 4. Serum hCG levels are obtained on days 1, 4, and 7. If on day 7:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum hCG declines &gt;15 percent from the previous measurement, treatment is stopped, and the surveillance phase (which consists of weekly measurement of hCG until it is undetectable) begins.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum hCG measurement declines &lt;15 percent, a <strong>third</strong> dose of MTX may be administered on day 7, and hCG is reassessed on day 11. A <strong>fourth</strong> dose of MTX may be administered on day 11 for insufficient decline in hCG, with subsequent reassessment on day 14. If there continues to be an insufficient hCG decline at that point, surgery should be considered.</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Patients with an interstitial pregnancy: Multiple-dose</span><span class="headingEndMark"> — </span>Successful medical management of interstitial pregnancy (located at the junction of the fallopian tube and uterine cavity) was first reported with a multiple-dose protocol  (<a class="graphic graphic_figure graphicRef55921" href="/z/d/graphic/55921.html" rel="external">figure 1</a> and <a class="graphic graphic_table graphicRef56738" href="/z/d/graphic/56738.html" rel="external">table 1</a>). The most common regimen is the administration of MTX (1 <strong>mg/kg</strong> body weight per day IM or intravenously; maximum dose 100 mg in patients with normal renal function) on days 1, 3, 5, and 7 and IM <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (0.1 mg/kg) on days 2, 4, 6, and 8 [<a href="#rid21">21</a>]. Serum hCG levels are drawn on days 1, 3, 5, and 7. If the serum hCG declines &gt;15 percent from the previous measurement, treatment is stopped, and a surveillance phase begins.</p><p>The surveillance phase consists of weekly hCG measurements. If the hCG declines &lt;15 percent from the previous level, the patient is given an additional dose of MTX 1 <strong>mg/kg</strong> IM followed the next day with a dose of IM <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> 0.1 mg/kg. The hCG is followed until the level is undetectable. In one study, the mean duration to achieve an undetectable serum hCG concentration was 43±64 days [<a href="#rid22">22</a>]. A residual interstitial mass or heterogeneous area with persistent vascularity on ultrasound has been reported despite complete hCG resolution [<a href="#rid23">23,24</a>]. </p><p>Interstitial pregnancies managed with selective arterial embolization, local injection of MTX, or local injection of <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">potassium chloride</a>, with or without systemic MTX have also been described, and local injection of MTX may be associated with improved success rates [<a href="#rid25">25-28</a>]. In one retrospective study including 38 patients with interstitial pregnancy treated medically, those treated with systemic compared with local MTX had lower rates of pregnancy resolution (46.7 versus 87.5 percent, respectively); the regimens of MTX treatment varied [<a href="#rid28">28</a>].</p><p>Surgical treatment of interstitial pregnancy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3306.html" rel="external">"Tubal ectopic pregnancy: Surgical treatment", section on 'Interstitial pregnancy'</a>.)</p><p class="headingAnchor" id="H241222455"><span class="h2">Patients with other sites of ectopic pregnancy</span><span class="headingEndMark"> — </span>Medical and surgical management of other sites of ectopic pregnancy (ie, heterotopic, cervical, abdominal), and abnormally implanted intrauterine pregnancies (ie, cesarean scar pregnancy) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/112852.html" rel="external">"Ectopic pregnancy: Choosing a treatment", section on 'Heterotopic pregnancy'</a> and  <a class="medical medical_review" href="/z/d/html/3283.html" rel="external">"Cervical pregnancy: Diagnosis and management"</a> and  <a class="medical medical_review" href="/z/d/html/132045.html" rel="external">"Abdominal pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/131912.html" rel="external">"Cesarean scar pregnancy"</a>.)</p><p class="headingAnchor" id="H1531386463"><span class="h1">POSTTREATMENT INSTRUCTIONS AND COUNSELING</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Instructions</strong> – Patients should adhere to the following instructions during MTX treatment [<a href="#rid16">16</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Avoid vaginal intercourse and new conception until human chorionic gonadotropin (hCG) is undetectable.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Avoid pelvic examinations during surveillance of MTX therapy due to theoretical risk of tubal rupture.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Avoid sun exposure to limit risk of MTX dermatitis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Avoid vitamins containing <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>It is common advice to avoid nonsteroidal antiinflammatory drugs (NSAIDs), as the interaction with MTX may decrease renal excretion of MTX and increase the risk of toxicity. However, for rheumatologic disease, low-dose MTX is sometimes given concurrently with NSAIDs along with close monitoring; the dose given for ectopic pregnancy is considered an intermediate dose. (See  <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Pharmacology'</a> and  <a class="medical medical_review" href="/z/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate", section on 'Potential drug-drug-interactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Counseling about pain after treatment</strong> – Mild to moderate abdominal pain of short duration (one to two days) at six to seven days after receiving the MTX is common. The pain may be due to tubal abortion or tubal distention from hematoma formation and can usually be controlled with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>. </p><p></p><p class="bulletIndent1">By contrast, severe abdominal pain is concerning for tubal rupture. Such patients should be further evaluated with transvaginal ultrasonography; findings suggestive of hemoperitoneum raise clinical suspicion of tubal rupture. In one study, three parameters predicted hemoperitoneum ≥300 mL in patients with ectopic pregnancy: moderate to severe pelvic pain, fluid above the uterine fundus or around the ovary, and hemoglobin concentration &lt;10 g/dL [<a href="#rid29">29</a>]. A patient with none of these three criteria had a probability of 5.3 percent of hemoperitoneum ≥300 mL. When two or more criteria were present, the probability for hemoperitoneum ≥300 mL reached 92.6 percent.</p><p></p><p class="bulletIndent1">If hemoperitoneum is not found on ultrasound, patients with severe pain should be closely observed for hemodynamic changes which may accompany tubal rupture. Falling hCG levels do <strong>not</strong> preclude the possibility of tubal rupture. If tubal rupture is suspected, immediate surgery is required. (See  <a class="medical medical_review" href="/z/d/html/3306.html" rel="external">"Tubal ectopic pregnancy: Surgical treatment"</a>.)</p><p></p><p class="bulletIndent1">Severe pain alone in a hemodynamically stable patient is not an indication for surgery. As an example, in a review including 56 patients with ectopic pregnancy and managed with ectopic pregnancy, presenting with abdominal pain severe enough to be evaluated in the clinic or emergency department or requiring hospitalization, only eight patients subsequently required surgery [<a href="#rid30">30</a>].</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUBSEQUENT PREGNANCY</span><span class="headingEndMark"> — </span>The safe interval from MTX treatment to conception is unclear and there are no studies addressing the earliest time to conceive after MTX treatment of ectopic pregnancy. In our practice, we advise patients not to conceive for three months [<a href="#rid16">16</a>]. However, there is no evidence of teratogenic risk to those who conceive sooner [<a href="#rid31">31</a>]. All patients trying to conceive should take folate daily, according to routine preconception recommendations. (See  <a class="medical medical_review" href="/z/d/html/423.html" rel="external">"Preconception and prenatal folic acid supplementation"</a>.)</p><p>Toxicology literature recommends a four- to six-month washout period before attempting to become pregnant [<a href="#rid32">32</a>], and residual MTX may be stored in the liver and kidney for months. However, in a retrospective study including patients who conceive after MTX treatment for ectopic pregnancy, those who conceived within &lt;6 compared with ≥6 months, rates of fetal malformation and adverse outcome were similar between groups [<a href="#rid33">33</a>]. </p><p>MTX treatment does not seem to affect future fertility rates. In a meta-analysis of seven observational studies involving 327 patients with a history of ectopic pregnancy, the mean number of retrieved oocytes from in vitro fertilization cycles before and after MTX therapy was similar [<a href="#rid34">34</a>]. Baseline follicle-stimulating hormone level, duration of stimulation, total gonadotrophin dose used for stimulation, and estradiol level on ovulation trigger before and after MTX treatment were also comparable. </p><p>After medical treatment of an interstitial pregnancy (see <a class="local">'Patients with an interstitial pregnancy: Multiple-dose'</a> above), there is an unknown risk of uterine rupture in a subsequent pregnancy [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H31314886"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118506.html" rel="external">"Society guideline links: Ectopic pregnancy"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15856.html" rel="external">"Patient education: Ectopic pregnancy (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/6723.html" rel="external">"Patient education: Ectopic (tubal) pregnancy (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indication</strong> – <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> (MTX) is used to treat selected patients with a tubal ectopic pregnancy who are able and willing to comply with close follow-up  (<a class="graphic graphic_algorithm graphicRef114571" href="/z/d/graphic/114571.html" rel="external">algorithm 1</a>). How to choose between MTX and surgery and contraindications to MTX are also illustrated in the algorithm and are discussed in detail separately. (See <a class="local">'Indications and alternatives'</a> above and  <a class="medical medical_review" href="/z/d/html/112852.html" rel="external">"Ectopic pregnancy: Choosing a treatment", section on 'Choosing between methotrexate and surgery'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment testing</strong> – Pretreatment testing includes serum human chorionic gonadotropin (hCG), transvaginal ultrasound, complete blood count, blood type and screen, and renal and liver function tests. (See <a class="local">'Pretreatment evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical protocol </strong> (<a class="graphic graphic_table graphicRef56738" href="/z/d/graphic/56738.html" rel="external">table 1</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Most patients: Single-dose protocol</strong> – For most patients with a tubal pregnancy treated with MTX, we suggest a single-dose rather than a multi-dose regimen (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). While the overall rate of resolution of ectopic pregnancy is similar, the single-dose protocol appears to cause fewer adverse effects. As an alternative, some physicians plan for a two-dose protocol for selected patients (eg, hCG &gt;3000 milli-international units/mL, adnexal masses &gt;2 cm), however, we do <strong>not</strong> use this protocol in our practice. (See <a class="local">'Preferred approach for most patients: Single-dose'</a> above and <a class="local">'Comparing single- versus multi-dose therapy'</a> above and <a class="local">'Role of two-dose protocol'</a> above.)</p><p></p><p class="bulletIndent2">In single-dose protocols, intramuscular (IM) MTX 50 mg/m<sup>2</sup> (maximum dose 100 mg in patients with normal renal function) is given followed by an hCG level on treatment days 4 and 7 and then weekly. If the decrease in hCG between days 4 and 7 is &lt;15 percent, a second dose of MTX is administered. Additional doses of MTX are given if the hCG level does not decline sufficiently. Serum hCG is then followed until the level is undetectable. (See <a class="local">'Preferred approach for most patients: Single-dose'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with interstitial pregnancy: Multiple-dose</strong> <strong>protocol</strong> – For patients with an interstitial pregnancy, we suggest a multiple-dose protocol (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, reasonable alternatives include selective arterial embolization or local injection of MTX or <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">potassium chloride</a>, with or without systemic MTX. Limited data suggest local injection of MTX may be associated with improved success rates, however, it requires administration by an experienced physician and is highly operator dependent. (See <a class="local">'Patients with an interstitial pregnancy: Multiple-dose'</a> above and <a class="local">'Dosing and administration'</a> above.)</p><p></p><p class="bulletIndent2">In multiple-dose protocols, MTX is given on days 1, 3, 5, and 7 and <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> on days 2, 4, 6, and 8. If the serum hCG concentration plateaus or increases in two consecutive measurements, a second course may be given seven days after the previous dose. HCG is followed weekly until undetectable. (See <a class="local">'Patients with an interstitial pregnancy: Multiple-dose'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other patients</strong> – Management of patients with other sites of ectopic pregnancy (eg, heterotopic, cervical, abdominal) or abnormally implanted intrauterine pregnancy (ie, cesarean scar) are discussed in detail separately. (See <a class="local">'Patients with other sites of ectopic pregnancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Posttreatment counseling</strong> – Mild abdominal pain of short duration (one to two days) that occurs six to seven days after receiving the medication is common. Patients with severe pain should be observed closely for hemodynamic changes which may accompany a tubal rupture. Clinical suspicion of a tubal rupture is an indication for immediate surgery. (See <a class="local">'Posttreatment instructions and counseling'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent pregnancy</strong> – In our practice, we advise patients not to conceive for three months, however, there is no evidence of teratogenic risk to those who conceive sooner. All patients trying to conceive should take folate daily, according to routine preconception recommendations. (See <a class="local">'Subsequent pregnancy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 1978; 41:36.</a></li><li><a class="nounderline abstract_t">Lipscomb GH. Medical therapy for ectopic pregnancy. Semin Reprod Med 2007; 25:93.</a></li><li><a class="nounderline abstract_t">Hajenius PJ, Mol F, Mol BW, et al. Interventions for tubal ectopic pregnancy. Cochrane Database Syst Rev 2007; :CD000324.</a></li><li><a class="nounderline abstract_t">Barnhart KT, Gosman G, Ashby R, Sammel M. The medical management of ectopic pregnancy: a meta-analysis comparing "single dose" and "multidose" regimens. Obstet Gynecol 2003; 101:778.</a></li><li><a class="nounderline abstract_t">Lipscomb GH, Givens VM, Meyer NL, Bran D. Comparison of multidose and single-dose methotrexate protocols for the treatment of ectopic pregnancy. Am J Obstet Gynecol 2005; 192:1844.</a></li><li><a class="nounderline abstract_t">Alur-Gupta S, Cooney LG, Senapati S, et al. Two-dose versus single-dose methotrexate for treatment of ectopic pregnancy: a meta-analysis. Am J Obstet Gynecol 2019; 221:95.</a></li><li><a class="nounderline abstract_t">Jermy K, Thomas J, Doo A, Bourne T. The conservative management of interstitial pregnancy. BJOG 2004; 111:1283.</a></li><li><a class="nounderline abstract_t">Xiao C, Shi Q, Cheng Q, Xu J. Non-surgical management of tubal ectopic pregnancy: A systematic review and meta-analysis. Medicine (Baltimore) 2021; 100:e27851.</a></li><li><a class="nounderline abstract_t">Nilsson UW, Johns TG, Wilmann T, et al. Effects of gefitinib, an epidermal growth factor receptor inhibitor, on human placental cell growth. Obstet Gynecol 2013; 122:737.</a></li><li><a class="nounderline abstract_t">Skubisz MM, Horne AW, Johns TG, et al. Combination gefitinib and methotrexate compared with methotrexate alone to treat ectopic pregnancy. Obstet Gynecol 2013; 122:745.</a></li><li><a class="nounderline abstract_t">Horne AW, Tong S, Moakes CA, et al. Combination of gefitinib and methotrexate to treat tubal ectopic pregnancy (GEM3): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2023; 401:655.</a></li><li><a class="nounderline abstract_t">Lipscomb GH, Bran D, McCord ML, et al. Analysis of three hundred fifteen ectopic pregnancies treated with single-dose methotrexate. Am J Obstet Gynecol 1998; 178:1354.</a></li><li><a class="nounderline abstract_t">Stovall TG, Ling FW, Gray LA, et al. Methotrexate treatment of unruptured ectopic pregnancy: a report of 100 cases. Obstet Gynecol 1991; 77:749.</a></li><li><a class="nounderline abstract_t">Stovall TG, Ling FW. Single-dose methotrexate: an expanded clinical trial. Am J Obstet Gynecol 1993; 168:1759.</a></li><li><a class="nounderline abstract_t">Kirk E, Condous G, Van Calster B, et al. A validation of the most commonly used protocol to predict the success of single-dose methotrexate in the treatment of ectopic pregnancy. Hum Reprod 2007; 22:858.</a></li><li><a class="nounderline abstract_t">Practice Committee of American Society for Reproductive Medicine. Medical treatment of ectopic pregnancy: a committee opinion. Fertil Steril 2013; 100:638.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 193: Tubal Ectopic Pregnancy. Obstet Gynecol 2018; 131:e91. Reaffirmed 2022.</a></li><li><a class="nounderline abstract_t">Natale A, Candiani M, Barbieri M, et al. Pre- and post-treatment patterns of human chorionic gonadotropin for early detection of persistence after a single dose of methotrexate for ectopic pregnancy. Eur J Obstet Gynecol Reprod Biol 2004; 117:87.</a></li><li><a class="nounderline abstract_t">Saraj AJ, Wilcox JG, Najmabadi S, et al. Resolution of hormonal markers of ectopic gestation: a randomized trial comparing single-dose intramuscular methotrexate with salpingostomy. Obstet Gynecol 1998; 92:989.</a></li><li><a class="nounderline abstract_t">Gamzu R, Almog B, Levin Y, et al. The ultrasonographic appearance of tubal pregnancy in patients treated with methotrexate. Hum Reprod 2002; 17:2585.</a></li><li><a class="nounderline abstract_t">Stovall TG, Ling FW, Buster JE. Outpatient chemotherapy of unruptured ectopic pregnancy. Fertil Steril 1989; 51:435.</a></li><li><a class="nounderline abstract_t">Lau S, Tulandi T. Conservative medical and surgical management of interstitial ectopic pregnancy. Fertil Steril 1999; 72:207.</a></li><li><a class="nounderline abstract_t">Verity L, Ludlow J, Dickinson JE. Interstitial ectopic pregnancy: a contemporary case series. Aust N Z J Obstet Gynaecol 2003; 43:232.</a></li><li><a class="nounderline abstract_t">Tang A, Baartz D, Khoo SK. A medical management of interstitial ectopic pregnancy: a 5-year clinical study. Aust N Z J Obstet Gynaecol 2006; 46:107.</a></li><li><a class="nounderline abstract_t">Monteagudo A, Minior VK, Stephenson C, et al. Non-surgical management of live ectopic pregnancy with ultrasound-guided local injection: a case series. Ultrasound Obstet Gynecol 2005; 25:282.</a></li><li><a class="nounderline abstract_t">Deruelle P, Lucot JP, Lions C, Robert Y. Management of interstitial pregnancy using selective uterine artery embolization. Obstet Gynecol 2005; 106:1165.</a></li><li><a class="nounderline abstract_t">Ophir E, Singer-Jordan J, Oettinger M, et al. Uterine artery embolization for management of interstitial twin ectopic pregnancy: case report. Hum Reprod 2004; 19:1774.</a></li><li><a class="nounderline abstract_t">Kim MJ, Cha JH, Bae HS, et al. Therapeutic outcomes of methotrexate injection in unruptured interstitial pregnancy. Obstet Gynecol Sci 2017; 60:571.</a></li><li><a class="nounderline abstract_t">Fauconnier A, Mabrouk A, Salomon LJ, et al. Ultrasound assessment of haemoperitoneum in ectopic pregnancy: derivation of a prediction model. World J Emerg Surg 2007; 2:23.</a></li><li><a class="nounderline abstract_t">Lipscomb GH, Puckett KJ, Bran D, Ling FW. Management of separation pain after single-dose methotrexate therapy for ectopic pregnancy. Obstet Gynecol 1999; 93:590.</a></li><li><a class="nounderline abstract_t">Kung FT, Chang SY, Tsai YC, et al. Subsequent reproduction and obstetric outcome after methotrexate treatment of cervical pregnancy: a review of original literature and international collaborative follow-up. Hum Reprod 1997; 12:591.</a></li><li class="breakAll">Strauss JF, Williams CJ. The ovarian life cycle. In: Yen and Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management, 5th ed, Strauss JF, Barbieri RL (Eds), Elsevier Saunders, Philadelphia 2004. p.213.</li><li><a class="nounderline abstract_t">Svirsky R, Rozovski U, Vaknin Z, et al. The safety of conception occurring shortly after methotrexate treatment of an ectopic pregnancy. Reprod Toxicol 2009; 27:85.</a></li><li><a class="nounderline abstract_t">Ohannessian A, Loundou A, Courbière B, et al. Ovarian responsiveness in women receiving fertility treatment after methotrexate for ectopic pregnancy: a systematic review and meta-analysis. Hum Reprod 2014; 29:1949.</a></li><li><a class="nounderline abstract_t">Downey GP, Tuck SM. Spontaneous uterine rupture during subsequent pregnancy following non-excision of an interstitial ectopic gestation. Br J Obstet Gynaecol 1994; 101:162.</a></li></ol></div><div id="topicVersionRevision">Topic 5407 Version 51.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/342086" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The clinical pharmacology of methotrexate: new applications of an old drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17377896" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Medical therapy for ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17253448" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Interventions for tubal ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12681886" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The medical management of ectopic pregnancy: a meta-analysis comparing "single dose" and "multidose" regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15970826" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparison of multidose and single-dose methotrexate protocols for the treatment of ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30629908" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Two-dose versus single-dose methotrexate for treatment of ectopic pregnancy: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15521876" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The conservative management of interstitial pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34918633" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Non-surgical management of tubal ectopic pregnancy: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24084529" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effects of gefitinib, an epidermal growth factor receptor inhibitor, on human placental cell growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24084530" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Combination gefitinib and methotrexate compared with methotrexate alone to treat ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36738759" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Combination of gefitinib and methotrexate to treat tubal ectopic pregnancy (GEM3): a multicentre, randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9662322" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Analysis of three hundred fifteen ectopic pregnancies treated with single-dose methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2014090" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Methotrexate treatment of unruptured ectopic pregnancy: a report of 100 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8317518" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Single-dose methotrexate: an expanded clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17088266" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A validation of the most commonly used protocol to predict the success of single-dose methotrexate in the treatment of ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23849842" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Medical treatment of ectopic pregnancy: a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29470343" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : ACOG Practice Bulletin No. 193: Tubal Ectopic Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15474251" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pre- and post-treatment patterns of human chorionic gonadotropin for early detection of persistence after a single dose of methotrexate for ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9840564" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Resolution of hormonal markers of ectopic gestation: a randomized trial comparing single-dose intramuscular methotrexate with salpingostomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12351533" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The ultrasonographic appearance of tubal pregnancy in patients treated with methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2784113" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Outpatient chemotherapy of unruptured ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10438980" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Conservative medical and surgical management of interstitial ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14712991" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Interstitial ectopic pregnancy: a contemporary case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16638031" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A medical management of interstitial ectopic pregnancy: a 5-year clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15736204" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Non-surgical management of live ectopic pregnancy with ultrasound-guided local injection: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16260556" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Management of interstitial pregnancy using selective uterine artery embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15218007" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Uterine artery embolization for management of interstitial twin ectopic pregnancy: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29184866" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Therapeutic outcomes of methotrexate injection in unruptured interstitial pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17825105" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Ultrasound assessment of haemoperitoneum in ectopic pregnancy: derivation of a prediction model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10214839" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Management of separation pain after single-dose methotrexate therapy for ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9130765" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Subsequent reproduction and obstetric outcome after methotrexate treatment of cervical pregnancy: a review of original literature and international collaborative follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9130765" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Subsequent reproduction and obstetric outcome after methotrexate treatment of cervical pregnancy: a review of original literature and international collaborative follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19103279" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The safety of conception occurring shortly after methotrexate treatment of an ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25056087" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ovarian responsiveness in women receiving fertility treatment after methotrexate for ectopic pregnancy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7864910" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Spontaneous uterine rupture during subsequent pregnancy following non-excision of an interstitial ectopic gestation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
